Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24.
This article was originally published on MedicalXpress.com
Novo Nordisk to pay $2 billion for new weight loss drug
You may also be interested in:
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
The Latest
5 Popular Supplements in Canada for Optimal Health and Wellness
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
The Latest
PetVet Dx Revolutionizes Wildlife Conservation with AI and Molecular Diagnostics to Combat Incurable CWD in Deer and Elk
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
Read More:
-
At the height of the COVID-19 pandemic, firearm violence surpassed motor vehicle accidents as the leading cause of death among US children. A new study [...]
-
New Curtin University research has revealed child food insecurity in developed countries is not solely driven by poverty but is also strongly influenced by factors [...]
-
Researchers at Oregon Health & Science University’s Center for Mental Health Innovation have discovered that maternal diet during pregnancy, specifically during the third trimester, may [...]
